Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Cobas SARS-CoV-2 Test authorized for asymptomatic people

August 2021—Roche’s Cobas SARS-CoV-2 has received FDA emergency use authorization for testing individuals without symptoms or reasons to suspect COVID-19. This authorization supports the guidance update from the CDC to expand SARS-CoV-2 testing to include people without symptoms and applies to pooled samples containing up to and including six individual samples. Asymptomatic testing with the Cobas SARS-CoV-2 test is also available in countries accepting the CE mark.

Sarstedt BL 1200 Sort Connect

August 2021—Sarstedt introduced its BL 1200 Sort Connect, a preanalytical accessioning and sorting instrument that can be connected to integrated systems or analyzer lines. The unit features a bulk loader that requires no sorting or handling. Multiple tube sizes are accepted and barcodes are identified via the ID module.

LGC SeraCare blood TMB reference standards

August 2021—LGC SeraCare released two new blood tumor mutational burden reference standards, Seraseq Blood TMB Score 7 and Seraseq Blood TMB Score 26. The products complement the company’s Seraseq I-O portfolio of tissue-derived Seraseq gDNA TMB Score 7 and Score 26 and Seraseq FFPE TMB Score 7 and Score 26 products.

Reference materials for bilirubin, cholesterol, uric acid

August 2021—Verichem Laboratories offers liquid-stable, protein-based clinical reference materials for total and direct bilirubin assays. The Bilirubin Standard Kit, Tru-Zero Bilirubin Standard, and extended-range Level F Bilirubin Standard are intended for CLIA calibration verification with wet chemistry testing systems. Verichem’s BR2 Bilirubin Calibrator is available for use exclusively with the BR2 Bilirubin Stat Analyzer from Advanced Instruments.

Qiagen launches CE-marked Artus Prep&Amp

August 2021—Qiagen launched its Artus SARS-CoV-2 Prep&Amp UM Kit, which integrates a liquid-based sample preparation technology for COVID-19 testing that takes two minutes or less with the provided real-time PCR assay. The kit uses common transport media as the starting material and provides all reagents required for sample to result on suspected SARS-CoV-2 patient samples. The workflow can support up to 672 samples per cycler in an eight-hour shift.

FDA clears GSD’s B. burgdorferi VlsE-OspC IgG/IgM assay

August 2021—Gold Standard Diagnostics announced the availability of its FDA-cleared B. burgdorferi VlsE-OspC IgG/IgM recombinant ELISA screen. The OspC antigen is highly specific for the detection of IgM antibodies and produces a superior first-tier screen, the company says, when used in combination with the recombinant VlsE. True Lyme-negative samples are eliminated prior to second-tier testing.

Bio-Rad launches InteliQ Diabetes Control

July 2021—Bio-Rad Laboratories launched its InteliQ Diabetes Control, the 10th product offered in the InteliQ format. The InteliQ Diabetes Control includes three distinct levels that aim to address HbA1c precision monitoring needs of a wide range of test methods. InteliQ quality controls are designed to empower labs to automate their QC workflow with load-and-go efficiency, and users have access to the Unity data management program.

Diazyme launches beta-hydroxybutyrate assay

July 2021—Diazyme launched its FDA 510(k)–exempt Beta-Hydroxybutyrate Assay for the quantitative determination of beta-hydroxybutyrate. BHB serves as a guide for monitoring the progress of insulin therapy for diabetic ketoacid­osis and for patients presenting to the emergency room with documented hypoglycemia, acidosis, alcohol ingestion, or an unexplained increase in the anion gap.

Bio-Rad SARS-CoV-2 variant RT-PCR assays

July 2021—Bio-Rad Laboratories launched SARS-CoV-2 variant RT-PCR assays for research use only. The assays can detect SARS-CoV-2 variants of concern, including P.1, B.1.351, and B.1.1.7, by distinguishing specific mutations in SARS-CoV-2 using reverse transcription PCR, often prior to a next-generation–sequencing workflow for confirmation.

MARKETPLACE

TRENDING